Loading cancer entity…
Loading cancer entity…
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06462222 | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 45 | Guangzhou Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06762080 | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 36 | Guangzhou Medical UniversityOTHER | 1 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT06809530 | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05184816 | A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis | recruiting | Phase 1 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702305 | Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07674693 | Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases | not yet recruiting | Phase 1 | 29 | NYU Langone HealthOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07361705 | Zorifertinib With Osimertinib for NSCLC With Meningeal Progression | recruiting | Phase 1 | 42 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06431685 | Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer | recruiting | Phase 1 | 10 | Sichuan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | recruiting | Phase 1 / Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05598853 | Intrathecal Double Checkpoint Inhibition(IT-IO) | active not recruiting | Phase 1 | 26 | University of ZurichOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases(ReSPECT-LM) | active not recruiting | Phase 1 | 18 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials